Single-cell RNA-sequencing enables tracking and characterization of rare CLL cells with the potential to cause refractoriness.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00131049" target="_blank" >RIV/00216224:14740/23:00131049 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429134/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429134/</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Single-cell RNA-sequencing enables tracking and characterization of rare CLL cells with the potential to cause refractoriness.

Popis výsledku v původním jazyce

Chronic lymphocytic leukemia (CLL) is considered an incurable disease due to the limited ability of current treatment options to completely eradicate leukemic cells. The therapy selection pressure favors the preferential proliferation of rare resistant cells, leading to recurrent relapses. Early detection of these rare cells holds the potential to assist in selecting appropriate therapy. To explore the possibility to identify and characterize rare populations of CLL cells resistant to treatment and causing relapses, and trace the presence of such cells during the disease course by single-cell RNA sequencing (scRNA-seq).

Název v anglickém jazyce

Single-cell RNA-sequencing enables tracking and characterization of rare CLL cells with the potential to cause refractoriness.

Popis výsledku anglicky

Chronic lymphocytic leukemia (CLL) is considered an incurable disease due to the limited ability of current treatment options to completely eradicate leukemic cells. The therapy selection pressure favors the preferential proliferation of rare resistant cells, leading to recurrent relapses. Early detection of these rare cells holds the potential to assist in selecting appropriate therapy. To explore the possibility to identify and characterize rare populations of CLL cells resistant to treatment and causing relapses, and trace the presence of such cells during the disease course by single-cell RNA sequencing (scRNA-seq).

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů